Company news

Chimeric Therapeutics Limited news in 2025

Chimeric Therapeutics Limited's news releases, calls and decks from 2025, newest first.

View company

$8.4 M funding to drive CHM CDH17 and resignation of CMO

December 22, 2025

Trading Halt

December 18, 2025

CDH17 granted FDA Orphan Drug Designation for Gastric Cancer

December 7, 2025

Chimeric receives $4.5M R&D tax incentive

November 23, 2025

75% disease control observed in CHM CDH17 trial

November 12, 2025

CHM CORE NK Combination Phase 1b trial update

November 12, 2025

Pause in Trading

November 12, 2025

Response to ASX Query Letter

November 6, 2025

Additional complete responses in CHM CORE-NK Phase 1b trial

October 2, 2025

Disease control and tumour shrinkage observed in CHM CDH17

September 28, 2025

Appendix 4E and Annual Report

August 29, 2025

CHM CDH17 Clinical Trial Update

August 3, 2025

Chimeric receives $2.5 M advance on FY25 R&D tax incentive

June 10, 2025

CHM CDH17 receives FDA Fast Track

June 4, 2025

CHM CDH17 advances to dose level 2

May 20, 2025

$6.6 million Placement to advance clinical trial pipeline

May 20, 2025

ADVENT-AML Phase 1B clinical trial update

May 15, 2025

Completion of Entitlement Offer

April 24, 2025

Prospectus

March 17, 2025

Entitlement Offer to raise approximately $3.2 million

March 17, 2025

Reinstatement to Quotation

March 4, 2025

Chimeric announces intention to undertake Entitlement Offer

March 4, 2025

Suspension from Quotation

March 2, 2025

Half Year Report and Appendix 4D 31 December 2024

February 28, 2025

$4.0m Non-Dilutionary Funding

February 27, 2025

Decks in 2025